How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

被引：0
|
作者：
Michael Drummond
Oriana Ciani
Giulia Fornaro
Claudio Jommi
Eva Susanne Dietrich
Jaime Espin
Jean Mossman
Gerard de Pouvourville
机构：
[1] University of York,Centre for Health Economics
[2] CERGAS,Patient Representative and Visiting Senior Research Associate in the Medical Technology Research Group
[3] SDA Bocconi School of Management,undefined
[4] University of Bonn Pharmaceutical Institute,undefined
[5] Andalusian School of Public Health,undefined
[6] LSE Health,undefined
[7] London School of Economics,undefined
[8] ESSEC,undefined
来源：
BMC Health Services Research | / 23卷
关键词：
Cost-effectiveness analysis; Advanced therapy medicinal products; Health technology assessment; Managed entry agreements; Reimbursement;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] An assessment of health technology assessment in Canada
    Menon, D
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2000, 91 (02): : 120 - 120
  • [42] An Assessment of Health Technology Assessment in Canada
    Devidas Menon
    Canadian Journal of Public Health, 2000, 91 : 120 - 120
  • [43] Stem cells and beta cell replacement therapy: a prospective health technology assessment study
    Klemens Wallner
    Rene G. Pedroza
    Isaac Awotwe
    James M. Piret
    Peter A. Senior
    A. M. James Shapiro
    Christopher McCabe
    BMC Endocrine Disorders, 18
  • [44] Stem cells and beta cell replacement therapy: a prospective health technology assessment study
    Wallner, Klemens
    Pedroza, Rene G.
    Awotwe, Isaac
    Piret, James M.
    Senior, Peter A.
    Shapiro, A. M. James
    McCabe, Christopher
    BMC ENDOCRINE DISORDERS, 2018, 18
  • [45] Challenges of networking in technology assessment
    Coenen, R
    TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE, 1996, 51 (01) : 49 - 54
  • [46] Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
    Garrison, Louis P.
    Pezalla, Ed
    Towse, Adrian
    Yang, Hongbo
    Faust, Elizabeth
    Wu, Eric Q.
    Li, Nanxin
    Sawyer, Eileen K.
    Recht, Michael
    VALUE IN HEALTH, 2021, 24 (11) : 1628 - 1633
  • [47] Challenges posed by the precautionary principle and accountability in ecological risk assessment
    Matsuda, H
    ENVIRONMETRICS, 2003, 14 (02) : 245 - 254
  • [48] History of the international societies in health technology assessment: International Society for Technology Assessment in Health Care and Health Technology Assessment International
    Banta, David
    Jonsson, Egon
    Childs, Paul
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 19 - 23
  • [49] HOW TO INSTITUTIONALIZE THE "KNOWLEDGE TO ACTION" FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT?
    Espinoza, M. A.
    Cabieses, B.
    VALUE IN HEALTH, 2015, 18 (07) : A569 - A570
  • [50] DIFFERENCES IN EVIDENCE REQUIREMENTS IN ONCOLOGY DRUG ASSESSMENT BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES AND EMA AND HTA BODIES AMONG THEMSELVES
    Wolters, S.
    Jansen, C.
    Postma, M. J.
    VALUE IN HEALTH, 2020, 23 : S465 - S466
12345